| Date | Title | Description |
| 19.11.2025 | eDreams ODIGEO Sets New Accelerated Growth Target to Reach Over 13 Million Prime Members by 2030, 40% Above Market Consensus | eDreams ODIGEO (hereinafter, ‘The Company’ or ‘eDO’), the world’s leading travel subscription platform, today announced its new, highly ambitious long-term strategic roadmap.
Four years after unveiling its inaugural subscription-led strateg... |
| 10.05.2024 | Presidency update from Joint Steering Oversight Committee (JSOC), 9 May | Presidency update from the Joint Steering Oversight Committee (JSOC), chaired by Director-General in the Presidency, Ms Phindile Baleni
The South African Presidency and Business for South Africa (B4SA) continue to collaborate on strategic i... |
| 03.01.2024 | Global Mofy Metaverse Limited Announces the Closing of $10 Million Follow-on Offering | - |
| 29.12.2023 | Global Mofy Metaverse Limited Announces $10 Million Follow-on Offering | - |
| 20.10.2023 | Webuy Global Limited Announces Closing of $15.2 Million Initial Public Offering | - |
| 18.10.2023 | Webuy Global Limited Announces Pricing of $15.2 Million Initial Public Offering | - |
| 12.10.2023 | Global Mofy Metaverse Limited Announces Closing of $6,000,000 Initial Public Offering | - |
| 05.07.2023 | SRC Signs a 3-year Sponsorship Deal With Saudi Football Club Al Ittihad | SRC signs with Al Ittihad FC RIYADH, DUBAI, SAUDI ARABIA, July 5, 2023/EINPresswire.com/ -- The Saudi Real Estate Refinance Company (SRC), which is wholly owned by the Public Investment Fund (PIF), has signed a sponsorship deal with the Sau... |
| 13.06.2023 | Autifony Therapeutics announces commencement of a US Phase Ib study of AUT00201, a novel Kv3 modulator, in Progressive Myoclonic Epilepsy-7 (EPM7) | Stevenage, UK - 13 June 2023 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and other serious brain diseases, today announced that a Phase Ib trial... |
| 10.06.2023 | HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | /EIN News/ -- NEW YORK and VIENNA, Austria, June 10, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announce... |
| 17.04.2023 | VCI Global Limited Announces Closing of $5.12 Million Initial Public Offering | /EIN News/ -- KUALA LUMPUR, Malaysia, April 17, 2023 (GLOBE NEWSWIRE) -- VCI Global Limited (NASDAQ: VCIG) (“VCI Global”, or the “Company”) today announced the closing of its initial public offering (the “Offering”) of 1,280,000 ordinary sh... |
| 17.04.2023 | VCI Global Limited Announces Closing of $5.12 Million Initial Public Offering | - |
| 14.04.2023 | HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | /EIN News/ -- NEW YORK and VIENNA, Austria, April 14, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, the “Company”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today ann... |
| 29.11.2022 | Poolbeg Pharma PLC Announces Influenza AI model build completed | Influenza Artificial Intelligence model build completed
CytoReason analysis of human challenge trial data on track to deliver outputs in Q2 2023
LONDON, UK / ACCESSWIRE / November 29, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) 'Poolbeg' ... |
| 17.11.2022 | Poolbeg Pharma PLC Announces Capital Markets Day | LONDON, UK / ACCESSWIRE / November 17, 2022 / Poolbeg Pharma POLBPOLBF, 'Poolbeg' or the 'Company', a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it will be holding a C... |
| 17.11.2022 | Poolbeg Pharma PLC Announces Capital Markets Day | LONDON, UK / ACCESSWIRE / November 17, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company', a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it will ... |
| 08.11.2022 | Poolbeg Pharma PLC Announces AI Programme Yields Novel RSV Drug Targets | First time AI has been used to identify disease targets in RSV
LONDON, UK / ACCESSWIRE / November 8, 2022 / Poolbeg Pharma POLBPOLBF ('Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a unique capi... |
| 20.10.2022 | HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers | Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed novel arenaviral immunotherapy
HOOKIPA to receive $25 million in upfront cash as well as potential future success-based milestone payments up t... |
| 04.10.2022 | Poolbeg Pharma PLC Announces POLB 001 US Patent update | Continued expansion of IP portfolio enhancing protection of Poolbeg's growing pipeline
LONDON, UK / ACCESSWIRE / October 4, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) 'Poolbeg' or the 'Company'), a clinical stage infectious disease pharm... |
| 29.07.2022 | Poolbeg Pharma PLC Announces Appointment of Joint Broker | LONDON, UK / ACCESSWIRE / July 29, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ('Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has appointed Singer Capit... |
| 20.07.2022 | Poolbeg Pharma PLC Announces POLB001 Human Challenge Clinical Trial To Commence | Major milestone reached as POLB 001 human challenge clinical trial ready to commence
Regulatory approval gives green light for trial to proceed
LONDON, UK / ACCESSWIRE / July 20, 2022 / Poolbeg Pharma (Poolbeg Pharma plc) (AIM:POLB)(OTCQB:P... |
| 08.07.2022 | Global SPAC Partners Announces Confirmation of $41.9 million PIPE Financing and Gorilla's Waiver of $50 million Minimum Cash Condition | New York NY, July 08, 2022 (GLOBE NEWSWIRE) -- Global SPAC Partners Co. (“Global”) (Nasdaq: “GLSPU” for units, “GLSPT” for subunits and “GLSPW” for warrants) announces the confirmation of a $41.9 million PIPE financing.
Pursuant to the Amen... |
| 16.05.2022 | HOOKIPA Pharma Reports First Quarter 2022 Financial Results and Recent Highlights | HB-200 program on track to report Phase 1 data mid-year, Phase 2 data in combination with pembrolizumab in second half of 2022
Q1 capital raise and Gilead collaboration funding generated a strong cash position of $142 million
NEW YORK and V... |
| 09.05.2022 | HOOKIPA Pharma to Report First Quarter 2022 Financial Results on May 16, 2022 | NEW YORK and VIENNA, Austria, May 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will ... |
| 03.05.2022 | HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May | NEW YORK and VIENNA, Austria, May 03, 2022 (GLOBE NEWSWIRE) -- New York, US and Vienna, Austria, May 2, 2022 - HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary ar... |
| 13.04.2022 | HOOKIPA to Participate in the Kempen Life Sciences Conference | NEW YORK and VIENNA, Austria, April 13, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the co... |
| 04.04.2022 | Poolbeg Pharma PLC Announces Result of AGM | LONDON, UK / ACCESSWIRE / April 4, 2022 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, 'Poolbeg' or the 'Company') a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that at the Annual... |
| 31.03.2022 | Poolbeg Pharma PLC Announces POLB001 Update - Clinical Trial Agreement Signed | On track to commence LPS human challenge clinical trial in June 2022
LONDON, UK / ACCESSWIRE / March 31, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), ('Poolbeg' or the 'Company') announces that it has signed a Clinical Trial Agreement wit... |
| 30.03.2022 | Poolbeg Pharma PLC Announces Commencement of Trading on US OTCQB Market | Poolbeg Pharma commences trading on OTCQB Market in the United States
LONDON, UK / ACCESSWIRE / March 30, 2022 / Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a uniqu... |
| 24.03.2022 | HOOKIPA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Outlook | Lead oncology candidate HB-200 demonstrated high antigen-specific T cell responses and encouraging anti-tumor activity in heavily pre-treated head and neck cancer patients
HOOKIPA received FDA Fast Track designation and advanced HB-200 to P... |
| 02.03.2022 | HOOKIPA Pharma Announces Pricing of $75.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock | NEW YORK and VIENNA, Austria, March 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the pricing of an unde... |
| 15.02.2022 | HOOKIPA and Gilead Amend Collaboration and License Agreement to Develop Immunotherapies Against HIV | HOOKIPA to develop arenaviral-based therapeutic for HIV through Phase 1b clinical trial completion; Gilead has exclusive rights for further program development thereafter
Financial terms include $15 million initiation fee and $35 million eq... |
| 09.02.2022 | HOOKIPA to Present at the SVB Leerink Global Healthcare Conference | NEW YORK and VIENNA, Austria, Feb. 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the com... |
| 04.02.2022 | Altus Announces Leadership Transition Plan, Preliminary Financial Results & Normal Course Issuer Bid | Conference Call Scheduled for 5:30 pm ET Today
TORONTO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Altus Group Limited (TSX: AIF) (the “Company” or “Altus”), a leading provider of software, data solutions and independent advisory services to the glo... |
| 03.02.2022 | Altus Announces Leadership Transition Plan, Preliminary Financial Results & Normal Course Issuer Bid | TORONTO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Altus Group Limited (TSX: AIF) (the “Company” or “Altus”), a leading provider of software, data solutions and independent advisory services to the global commercial real estate (“CRE”) industry, an... |
| 18.01.2022 | HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrolizumab for Treatment of Head and Neck Cancer and Reports FDA’s Fast Track Designation | First patient dosed with HB-200 and pembrolizumab combination for treatment of 1st-line advanced/metastatic head and neck cancer in Phase 2 arm of ongoing Phase 1/2 trial Fast Track Designation granted for HB-200 in combination with pembrol... |
| 04.01.2022 | HOOKIPA Pharma to Present at the H.C. Wainwright BioConnect Conference | NEW YORK and VIENNA, Austria, Jan. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Com... |
| 12.11.2021 | HOOKIPA Pharma to Participate in Upcoming Stifel 2021 Virtual Healthcare Conference | NEW YORK and VIENNA, Austria, Nov. 12, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA... |
| 10.11.2021 | HOOKIPA Pharma Reports Third Quarter 2021 Financial Results and Recent Highlights | Clinical collaboration with Merck & Co., Inc., Kenilworth, NJ, USA, set to evaluate HB-201 in combination with pembrolizumab in 1st- and 2nd-line HNSCC patientsBased on recent strong data updates, HOOKIPA advancing HB-201 to Phase 2, pr... |
| 09.11.2021 | HOOKIPA advances HB-200 program to Phase 2 and prioritizes oncology portfolio based on clinical data updates across its novel arenaviral platform | Based on positive interim Phase 1 data, HOOKIPA initiates Phase 2 study to assess HB-201 in combination with pembrolizumab in 1st and 2nd line head and neck cancer
Interim Phase 1 HB-200 data continue to show high levels of tumor-specific C... |
| 14.10.2021 | HOOKIPA announces publication on the benefits of its novel arenaviral immunotherapeutics in cancer in Frontiers in Oncology | Comprehensive review highlights potential of HOOKIPA’s versatile arenavirus platform as a new immunotherapy strategy to address critical unmet needs in cancer
Pre-clinical and clinical data showcase potent, tumor-specific CD8+ T cell respon... |
| 15.04.2021 | Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics | April 15, 2021 04:00 AM Eastern Daylight Time |
| 13.04.2021 | GLOBAL SPAC PARTNERS CO.
Global SPAC Partners Co. Announces Closing of $160 Million Initial Public Offering | New York, New York, April 13, 2021 (GLOBE NEWSWIRE) -- Global SPAC Partners Co. (“Global” or the “Company”) (NASDAQ: GLSPU) announced today that it closed its initial public offering of 16,000,000 units, at $10.00 per unit, resulting in gro... |
| 10.04.2021 | HOOKIPA PHARMA INC.
HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers | Preliminary data demonstrate a robust increase in HPV16+-specific T cells, including up to 8% of circulating CD8+ T cells, after one dose of HB-201 or HB-202
Early data on HB-201 monotherapy show an increase in interferon-gamma and other im... |
| 09.04.2021 | GLOBAL SPAC PARTNERS CO.
Global SPAC Partners Co. Announces the Pricing of $160 Million Initial Public Offering | New York, New York, April 08, 2021 (GLOBE NEWSWIRE) -- Global SPAC Partners Co. (“Global” or the “Company”) (NASDAQ: GLSPU) announced today that it priced its initial public offering of 16,000,000 units, at $10.00 per unit. The units will b... |
| 26.03.2021 | LEKOIL LIMITED
Lekoil : Trading and operational update | RNS Number : 5635T Lekoil Limited
26 March 2021
26 March 2021
Lekoil Limited
("LEKOIL" or the "Company")
Trading and operational update
LEKOIL (AIM: LEK), the oil and gas exploration and production company with a focus o... |
| 23.03.2021 | Oxford BioDynamics announces US launch of its EpiSwitch® COVID-19 Severity Test (CST) | OXFORD, England--(BUSINESS WIRE)--Mar 23, 2021--
Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch ® 3D genomics platform, has laun... |
| 18.03.2021 | HOOKIPA Reports Fourth Quarter and Full Year 2020 Financial Results and Provides 2021 Outlook | Proprietary arenavirus immunotherapeutics platform demonstrated promising clinical activity with interim data from lead oncology and infectious disease candidates
Follow-on offering strengthened cash basis with $143 million available at yea... |
| 16.03.2021 | Alchemab and Medicines Discovery Catapult to develop landmark novel antibody therapy for Huntington’s disease | March 16, 2021 05:00 AM Eastern Daylight Time |
| 04.03.2021 | Pre-clinical data on HOOKIPA’s alternating 2-vector cancer therapeutics published in Cell Reports Medicine | Alternating, intravenous administration of two replicating arenaviral vectors induce tumor-specific responses exceeding 50% of the circulating CD8 T cells
2-vector approach resulted in tumor cures and long-term immunity against tumor rechal... |
| 23.02.2021 | Clinigen : Half Year Results for the Six Months Ended 31 December 2020 | 23 February 2021
Execution of strategy and simplification of structure to deliver accelerated mid-term growth plans
Clinigen Group plc (AIM: CLIN, 'Clinigen' or 'the Group'), the global pharmaceutical Products and Services group, has today ... |
| 23.02.2021 | CLINIGEN GROUP PLC
Clinigen : Execution of strategy and simplification of structure to deliver accelerated mid-term growth plans | 23 February 2021
Execution of strategy and simplification of structure to deliver accelerated mid-term growth plans
Clinigen Group plc (AIM: CLIN, 'Clinigen' or 'the Group'), the global pharmaceutical Products and Services group, has today ... |
| 23.02.2021 | Clinigen : Execution of strategy and simplification of structure to deliver accelerated mid-term growth plans | 23 February 2021
Execution of strategy and simplification of structure to deliver accelerated mid-term growth plans
Clinigen Group plc (AIM: CLIN, 'Clinigen' or 'the Group'), the global pharmaceutical Products and Services group, has today ... |
| 04.11.2019 | Volpi Capital expands team with the appointment of Eszter Santa | London, 04 November 2019: Volpi Capital (“Volpi”), a specialist European lower mid-market private equity firm, is pleased to announce the addition of Eszter Sánta to its investment team. Eszter’s appointment takes Volpi’s total headcount to... |
| 05.09.2019 | Volpi Capital completes management buyout of Asolvi | London, 5 September 2019: Volpi Capital (“Volpi”), a specialist European lower mid-market private equity firm, today announces its sixth deal with the management buyout of Asolvi, a European leader in field service management solutions, fro... |
| 20.08.2019 | Volpi Capital makes €20m investment into Mansystems | London, 20 August 2019: Volpi Capital (“Volpi”), a specialist European lower mid-market private equity firm, today announces an investment in excess of €20m into Mansystems, the leading Mendix implementation and support partner, headquarter... |
| 24.06.2019 | CDC Group and London Stock Exchange Group celebrate ‘Companies to Inspire Africa’ in Egypt | Cairo, Egypt: The second edition of London Stock Exchange Group’s (LSEG) ‘Companies to Inspire Africa’ report was presented today at the British Embassy in Cairo, Egypt – hosted by the British Ambassador to Egypt, Sir Geoffrey Adams. The re... |
| 05.06.2019 | Volpi Capital expands team with the appointment of Joerg Klasmeyer | London, 05 June 2019: Volpi Capital (“Volpi”), a specialist European lower mid-market private equity firm, is pleased to announce that Joerg Klasmeyer has joined its investment team, taking the business’ total headcount to 12, including 8 i... |
| 07.03.2019 | CycloMedia Acquires Floating Point FX to Fuel US and International Growth | Acquisition Strengthens CycloMedia’s US Presence, Enhances Data Analytics Capabilities |
| 06.03.2019 | Volpi Capital expands its investment team with the appointment of Erik Berggren | London, 6 March 2019: Volpi Capital (“Volpi”), a specialist European lower mid-market private equity firm, is pleased to announce that Erik Berggren has joined its investment team. Erik’s appointment takes Volpi’s total headcount to 11, inc... |
| 06.09.2017 | Congenica’s Sapientia™ selected for Portugal’s In2Genome genetic disease diagnosis project | Congenica’s Sapientia™ selected for Portugal’s In2Genome genetic disease diagnosis project
06-09-2017
Congenica, a global provider of clinical genomics interpretation software, today announced a new customer partnership with the Coimbra Pae... |
| 05.09.2017 | AMAL Therapeutics Raises €8 Million (CHF 8.8 Million) in First Closing of Series B Financing Round | Financing round co-led by Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund |
| 30.06.2017 | Marshall Group and Hill agree joint venture to bring hundreds of new homes to Cambridge | Marshall Group and Hill agree joint venture to bring hundreds of new homes to Cambridge
30-06-2017
Two of Cambridge’s leading family-owned businesses, Marshall Group Properties, part of the Marshall Group – one of the largest private employ... |
| 27.06.2017 | Mission Therapeutics appoints Scientific Advisory Board | Mission Therapeutics appoints Scientific Advisory Board
27-06-2017
Mission Therapeutics, a Babraham-based drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat serious diseases incl... |
| 22.06.2017 | China’s '100K Wellness Pioneer Project' uses UniteGen and Sapientia™ integrated platform | China’s '100K Wellness Pioneer Project' uses UniteGen and Sapientia™ integrated platform
22-06-2017
Congenica’s Sapientia™ clinical genome analysis software platform will be used by China-based UniteGen to carry out whole genome sequencing ... |
| 13.06.2017 | First accommodation milestone complete at University of Cambridge’s new district, Eddington | First accommodation milestone complete at University of Cambridge’s new district, Eddington
13-06-2017
Swirles Court, a development of 325 en-suite rooms, purpose built for students, has been completed at the North West Cambridge Developmen... |
| 05.06.2017 | F-star expands its relationship with Merck through a new strategic collaboration | F-star expands its relationship with Merck through a new strategic collaboration
05-06-2017
F-star, a biopharmaceutical company developing novel bispecific antibodies, announces today a new partnership with Merck, a leading science and tech... |
| 05.06.2017 | F-star expands its relationship with Merck through a new strategic collaboration | F-star, a biopharmaceutical company developing novel bispecific antibodies, announces today a new partnership with Merck, a leading science and technology company, for the development and commercialisation of five bispecific immuno-oncology... |
| 15.03.2017 | Autifony Therapeutics obtains £1.3 million in funding from Innovate UK and the Dementia Discovery Fund to explore novel approach to treatment of dementia | London, UK - 15th March 2017 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced a new funding award of £8... |
| 27.02.2017 | Congenica raises £8M ($10M) in Series B financing round to drive international expansion | Congenica, a leading provider of clinical genome analysis technology, announced today that it has raised £8m ($10m) in its Series B financing round. Existing investors, Cambridge Innovation Capital plc (CIC) and Amadeus Capital Partners par... |
| 27.02.2017 | Congenica raises £8M ($10M) in Series B financing round to drive international expansion | Congenica raises £8M ($10M) in Series B financing round to drive international expansion
27-02-2017
Congenica, a leading provider of clinical genome analysis technology, announced today that it has raised £8m ($10m) in its Series B financin... |
| 16.01.2017 | Quercus Realises More Than a 9% Return on the Disposal of Its Stake in ForVEI, a Renewable Energy Private Equity Joint Venture | MILAN & LONDON & DUBAI, United Arab Emirates–(BUSINESS WIRE)–January 16, 2017–
Quercus Assets Selection, which specialises in renewable infrastructure investments announces, from the World Future Energy Summit in Abu Dhabi, that the... |
| 09.12.2016 | Quercus Announces the €150 Million First Close of its New Renewable Energy Infrastructure Funds | LONDON & ROME & LUXEMBOURG–(BUSINESS WIRE)–December 9, 2016–
Quercus Assets Selection, which specialises in renewable infrastructure investments announces that it has reached its first close of €150 million, led by its Co-Founder an... |
| 10.12.2015 | ImmBio initiates first-in-human studies of its novel pneumococcal vaccine, PnuBioVax | ImmBio initiates first-in-human studies of its novel pneumococcal vaccine, PnuBioVax
10-12-2015
ImmunoBiology Ltd (ImmBio), a biopharmaceutical company developing next generation anti-infective vaccines based on its proprietary ImmBioVax™ t... |
| 15.10.2015 | Crescendo Biologics launches new strategy in oncology drug discovery & development | Crescendo Biologics launches new strategy in oncology drug discovery & development
15-10-2015
Crescendo Biologics Limited, the drug discovery and developer of Humabody™ VH therapeutics, has announced the launch of the Company’s new drug... |
| 12.06.2015 | Work begins on cutting-edge zero carbon development at Great Kneighton | Work begins on cutting-edge zero carbon development at Great Kneighton
12-06-2015
Leading housebuilder Hill has started work on its zero carbon development to the south of Cambridge which incorporates findings from its innovative Concept Ho... |
| - | Downing FOUR VCT Healthcare Share Class open for tax year-end investments | As the tax year draws to a close, the Downing FOUR Venture Capital Trust (VCT) Healthcare Share Class remains open for end of tax year investments as part of a £10.2m top-up offer.
The VCT, which is managed by investment manager Downing LL... |
| - | Pharm2Farm: Revolutionary Anti-viral Face Mask Kills 99.9% of Covid-19 Virus on Contact | NOTTINGHAM, England--(BUSINESS WIRE)--Mar 11, 2021--
A new anti-viral mask which kills 99.9% of Covid-19 virus within five minutes of contact has been launched today – offering an unparalleled level of protection against viruses not just fo... |
| - | AMAL Therapeutics finalises €29 million (CHF 33.2 million) Series B round | |
| - | Mission Therapeutics Welcomes Co-founder of Rosetta Capital, Jonathan Hepple, to its Board of Directors | CAMBRIDGE, England--(BUSINESS WIRE)--Mar 24, 2021--
Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announces the appointment of Jonathan He... |
| - | Amal Therapeutics raises CHF 3 million in a Series A financing round led by Boehringer Ingelheim Venture Fund | Amal Therapeutics (Amal) completes CHF 3 million (EUR 2.75 million) Series A financing round with Boehringer Ingelheim Venture Fund (BIVF) as cornerstone investors. VI Partners and High-Tech Gründerfonds also participated in the round which... |
| - | Neuromodulation pioneer WISE closes EUR 15M Series C financing round
to launch second product, SCS EXPERT, for chronic pain | WISE Srl, a medical device company developing next-generation implantable leads for neuromonitoring, neuromodulation and brain-machine interfacing, today announced the closing of a EUR 15 million Series C financing round. New investors, led... |
